PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HCV
Granted: December 23, 2010
Application Number:
20100324059
This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.
PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HCV
Granted: December 23, 2010
Application Number:
20100324060
This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.
PHARMACEUTICAL COMBINATIONS USEFUL FOR TREATING HCV
Granted: December 23, 2010
Application Number:
20100323989
This invention relates to combinations of Compound 1 and Compound 2 which are useful for treating hepatitis C virus infection.
ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS
Granted: December 9, 2010
Application Number:
20100310500
The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS
Granted: December 9, 2010
Application Number:
20100311794
The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS
Granted: December 2, 2010
Application Number:
20100305117
The invention provides 4,6-di- and 2,4,6-tri-substituted pteridine derivatives with a specific substitution pattern which exhibit a significant and selective activity against certain types of viral infections, in particular selectively inhibit replication of Flaviridae such as the hepatitis C virus, and are useful for the prevention and treatment of such viral infections.
PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS
Granted: November 18, 2010
Application Number:
20100292480
The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties.
TABLETS FOR COMBINATION THERAPY
Granted: November 11, 2010
Application Number:
20100285122
The invention provides solid dose forms (e.g. tablets) comprising a compound of Formula I, a compound of Formula II, a compound of Formula III and a salt of Formula IV.
CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT
Granted: August 12, 2010
Application Number:
20100203015
Provided are thieno[3,4-d]pyrimidin-7-yl and furo[3,4-d]pyrimidin-7-yl ribosides, riboside phosphates and prodrugs thereof as well as intermediates and methods of preparation. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.
MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
Granted: July 29, 2010
Application Number:
20100189687
The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
ANTIVIRAL COMPOUNDS
Granted: July 8, 2010
Application Number:
20100173939
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infection. R1 is:
METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS
Granted: June 24, 2010
Application Number:
20100160370
The present invention relates to methods, uses, and compositions comprising the caspase inhibitor (R)-N-((2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxo-tetrahydrofuran-3-yl)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.
HCV NS3 PROTEASE INHIBITORS
Granted: June 24, 2010
Application Number:
20100160403
The present invention relates to macrocyclic compounds of formula (Ia) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
NOVEL PYRIDAZINE COMPOUND AND USE THEREOF
Granted: June 17, 2010
Application Number:
20100152444
A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating compound (1) are provided.
4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS
Granted: June 10, 2010
Application Number:
20100143299
This invention provides the treatment of viral infections with a 4,6-disubstituted or 2,4,6-trisubstituted quinazoline derivative represented by the structural formula [(I)] wherein: R2 is selected from the group consisting of hydrogen, NR?R? and C1-7 alkyl; —A is selected from the group consisting of a bond, O, S(O)n, C1-7 alkylene, C2-7 alkenylene and C2-7 alkynylene; R4 is selected from the group consisting of C1-7 alkyl, C2-7 alkenyl, C3-10cycloalkyl, C3-10 cycloalkenyl, aryl,…
MODULATORS OF TOLL-LIKE RECEPTORS
Granted: June 10, 2010
Application Number:
20100143301
Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
Method of drug loading in liposomes by gradient
Granted: May 13, 2010
Application Number:
20100119590
A method for encapsulation of pharmaceutical agents (e.g., antineoplastic agents) in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes can be made by a process that loads the drug by an active mechanism using a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%. Drug:lipid ratios employed are higher than for older traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. After loading,…
NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT
Granted: April 29, 2010
Application Number:
20100104532
The invention provides unsaturated phosphonates of Formula I or a tautomer or pharmaceutically accepatble salt thereof, as described herein, as well as pharmaceutical compositions comprising the compounds, and therapeutic methods comprising administering the compounds. The compounds have anti-viral properties and are useful for treating viral infections (e.g. HCV) in animals (e.g. humans).
SALTS OF HIV INHIBITOR COMPOUNDS
Granted: April 15, 2010
Application Number:
20100093667
The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts.
NOVEL PYRIDAZINE COMPOUND AND USE THEREOF
Granted: March 11, 2010
Application Number:
20100063059
A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided.
